Histologic-based tumor microenvironment characteristics of serum inflamed tumor in clear cell renal cell carcinoma, Minoru Inoue, Keita Izumi, Akinori Nakayama, Chisato Ohe, Shinichi Ban, Kazutaka Saito., 25 Apr. 2024, Poster presentation
Algorithm for neoadjuvant chemotherapy in nonmetastatic upper tract urothelial carcinoma, Asumi Nirazuka, Keita Izumi, Erika Ikezoe, Minoru Inoue, Hiroki Tujioka, Kinastaro Hasegawa, Oosaka Akiyoshi, Yuka Yasuda, Akinori Nakayama, Kiyoshi Setoguchi, Kazutaka Saito., 25 Apr. 2024, Poster presentation
Testicular sperm retrieval in hemodialysis patients with sexual dysfunction, Akiyoshi Oosaka, Toshiyuki Iwahata, Erika Ikezoe, Minoru Inoue, Hiroki Tsujioka, Kintaro Hasegawa, Nirazuka Asumi, Miho Sugie, Yuka Yasuda, Keita izumi, Akinori Nakayama, Hiroshi Okada, Kazutaka Saito., 26 Apr. 2024, Poster presentation
Prognostic impact of bone metastasis in up front androgen receptor-axis-targeted therapy for metastatic castration-sensitinve prostate vancer prostate cancer, Akinori Nakayama, Erika Ikezoe, Minoru Inoue, Hiroki Tsujioka, Asumi nirazuka, keita Izumi, Kiyoshi Setoguchi, Kazutaka Saito., 26 Apr. 2024
Clinical significance of preoperarive CRP in intermediate-high risk clear cell renal cell carcinoma: Can a good prognosis group be selected?, Asumi Nirazuka, Akinori Nakayama, Erika Ikezoe, Minoru Inoue, Keita Izumi, Kiyoshi Setoguchi, Chisato Ohe, Shinichi Ban, Kazutaka Saito, The 112th Annual Meeting of the Japanese Urological Associarion, 17 Apr. 2025, 17 Apr. 2025, 19 Apr. 2025, Japan, False
Initial Experience with triplent therapy for metastatic castration senstive prostate cancer, Yusuke Hata, Akiyoshi Nakayama, Erika Ikezoe, Minoru inoue, Hiroki Tsujioka, Asumi Nirazuka, Kintaro Hasehgawa, Akiyoshi Oosaka, Keita Izumi, Toshiuki Iwahata, Kiyoshi Setoguchi, Kazutaka Saito, The 112th Annual Meeting of the Japanese Urological Associarion, 18 Apr. 2025, 17 Apr. 2025, 19 Apr. 2025, Poster presentation, Japan, False
Prognostic significance of Gleason Grade Group 5 in metastatic castration-sensitive prostate cancer treated with doublet therapy, 23 Apr. 2026, 23 Apr. 2026, 26 Apr. 2026, Oral presentation, False
Initial experience with enfortumab vedotin and pembrolizumab therapy for advanced urothelial carcinoma, 24 Apr. 2026, 23 Apr. 2026, 26 Apr. 2026, Poster presentation, False
Clinical outcomes of enfortumab vedotin in patients with metastatic urothelial carcinoma: a retrospective single-institution analysis, 24 Apr. 2026, 23 Apr. 2026, 26 Apr. 2026, Poster presentation, False
Adjuvant Therapy with Pembrolizumab in Renal Cell Carcinoma: Real-World Experiences, 25 Apr. 2026, 23 Apr. 2026, 26 Apr. 2026, Poster presentation, False